Bolstering Our Biologics Expertise
The Appointment of Sean O’Brien
San Diego, CA, 3rd April 2023 – Abzena, the leading end-to-end integrated CDMO for complex biologic molecules and Antibody Drug Conjugates (ADCs) has announced the appointment of Sean O’Brien as Senior Vice President and Site Head at its San Diego facility.
Sean will be responsible for leading and managing all site operations applying his extensive knowledge across areas including regulatory approval and manufacturing process improvements to benefit customer programs.
Sean joins Abzena with over 20 years of experience in the pharmaceutical industry gained from companies including Alexion Pharmaceuticals and Amgen. He will leverage his extensive experience in leading organizations and driving business and network improvements to ensure that Abzena’s customers benefit from a world-class biologics manufacturing service alongside the other market leading capabilities they offer.
Commenting on his appointment, Sean said: “I was drawn to Abzena’s commitment to driving continuous improvements across its operations as it strives to help customers realize the full potential of their investments in human health. I am looking forward to driving the San Diego site through the next phase of company growth”.
Matthew Stober, Chief Executive Officer, said: “Sean’s deep technical operations experience will ensure that Abzena can rapidly align to our customers' needs and robustly respond to their customized program requirements. His deep expertise in process development, manufacturing and quality will ensure that we are aligning our market leading capabilities with the global customer needs.”
For further information, images, and interview opportunities, please contact Imogen Quail at ramarketing: email@example.com | +44 (0)191222 1242 | ramarketingpr.com | Twitter | Facebook | Linkedin
About Abzena – Your Integrated Biologics CDMO
Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson Stowe, one of the world’s leading private equity investors.